

## Supplementary Method

**Survival curves for cancer patients expressing high and low levels of PI3K $\delta$ .** The survival curves showing the changes of survival rates along the time in cancer patients expressing high and low levels of PI3K $\delta$  were plotted using PanCanSurvPlot program (<https://smuonco.shinyapps.io/PanCanSurvPlot/>). PanCanSurvPlot retrieves microarray or RNA-sequencing data of cancer patients from the GEO and TCGA databases, and further performs the survival analysis [1]. The program collected a total of 215 cancer-related databases from the GEO and TCGA databases, covering ~45,000 samples from 51 different cancer types and 13 survival outcome datasets. The survival data analyses were performed using Kaplan-Meier method, and long-rank test and univariant Cox proportional hazard regression model was utilized to assess the correlation between gene expression profiles and clinical outcomes. The end users can define the patient groups with high and low expression levels of specific gene, based on the median or optimal cutoff values. In **Supplementary Figure S6**, we selected patient cohorts from PCa, breast, pancreatic, ovarian, endometrial, cervical, colon and lung cancers, and divided cancer patient groups with high and low PI3K $\delta$  expression levels based on 'optimal' cutoff values. The survival curves showing significantly lower survival rates ( $p$ -values < 0.05, long-rank test and univariant Cox proportional hazard regression) in patients expressing high PI3K $\delta$  vs. low PI3K $\delta$  were plotted.

1. Lin, A., Yang, H., Shi, Y., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022). PanCanSurvPlot: A Large-scale Pan-cancer Survival Analysis Web Application. *BioRxiv*, 2022.12.25.521884. <https://doi.org/10.1101/2022.12.25.521884>.

**Supplementary Table S1. Primer sequences used for the RT-PCR assays.**

<b>Primer ID</b>	<b>Nucleotide sequences</b>
PIK3CD-f	5'-CTGAGCTCTCAGAAGACC-3'
PIK3CD-r1	5'-GCTCGCGGTTGATTCCAA-3'
PIK3CD-r2	5'-AATAGCCAGCACAGGAGAGG-3'
EIF1AX-f	5'-GTACTGGAGAGGGGAGAGCA-3'
EIF1AX-r	5'-TGAAGCTGAGACAAGCAGGA-3'

**Supplementary Table S2. Quantification of PI3K $\delta$ -L and PI3K $\delta$ -S expression levels in PCa and other endocrine/solid tumor cell lines.** % of green (PI3K $\delta$ ) and red (PI3K $\delta$ -S) fluorescence-positive cells were counted by measuring (numbers of green signals/numbers of blue signals  $\times$  100%) and (numbers of red signals/numbers of blue signals  $\times$  100%) signals from the immunofluorescence assay results in **Figure 1D** and **2D**. Green (PI3K $\delta$ ) and red (PI3K $\delta$ -S) fluorescence intensities of each images from immunofluorescence assays in **Figure 1D** and **2D** were quantified using ImageJ, as described in Methods. In each cell line, green (PI3K $\delta$ ) fluorescence intensity was defined as 100%. Red (PI3K $\delta$ -S) intensity was quantified and normalized to the green (PI3K $\delta$ ) fluorescence intensity in each cell line. The PI3K $\delta$ -L intensities were calculated using equation of: 100% - (% of PI3K $\delta$ -S).

**A.**

	22Rv1	PC-3	LNCaP	DU-145	C42B	MDA PCa 2b
PI3K $\delta$ (+) cells, %	100	100	100	100	100	100
PI3K $\delta$ -S (+) cells, %	100	100	33	100	100	100
PI3K $\delta$ intensity, %	100	100	100	100	100	100
PI3K $\delta$ -S intensity, %	59	49	11	39	24	72
PI3K $\delta$ -L intensity, %	41	51	89	61	76	28
PI3K $\delta$ -S: PI3K $\delta$	3:5	1:2	1:9	1:2.5	1:4.2	7.2:10
PI3K $\delta$ -S/PI3K $\delta$ -L ratio (S/L ratio)	1.44	0.96	0.12	0.64	0.32	2.6

**B.**

	HT-29	SW620	A549	H1299	MDA MB 231	MCF-7
PI3K $\delta$ (+) cells, %	100	100	100	100	100	100
PI3K $\delta$ -S (+) cells, %	100	100	100	100	100	50
PI3K $\delta$ intensity, %	100	100	100	100	100	100
PI3K $\delta$ -S intensity, %	76	74	29	12	30	41
PI3K $\delta$ -L intensity, %	24	26	71	88	70	59
PI3K $\delta$ -S: PI3K $\delta$	1:1.3	0.75:1	1:3.5	1:10	1:3	1:2.5
PI3K $\delta$ -S/PI3K $\delta$ -L ratio (S/L ratio)	3.17	2.85	0.41	0.14	0.43	0.70